Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868852 | 0.80 | NQO1 (0.47) | TDP1KDM4EALDH1A1L3MBTL1TP53 | |
| SCHEMBL5476883 | 0.80 | IDO1 (0.41) | TDP1KDM4EPARP1ALDH1A1EPHX2 | |
| SCHEMBL1732578 | 0.80 | PARP1 (0.38) | TDP1KDM4EPARP1ALDH1A1EPHX2 | |
| SCHEMBL3327471 | 0.79 | CALM1 (0.46) | TDP1KDM4EPARP1ALDH1A1TP53 | |
| SCHEMBL223822 | 0.78 | — | — | |
| SCHEMBL13049960 | 0.78 | KDM4E (0.45) | TDP1KDM4EPARP1ALDH1A1L3MBTL1 | |
| SCHEMBL1733685 | 0.77 | PARP1 (0.39) | TDP1KDM4EPARP1ALDH1A1EPHX2 | |
| SCHEMBL12662844 | 0.76 | SMN1; SMN2 (0.35) | TDP1ALDH1A1L3MBTL1HTTSLC5A2 | |
| SCHEMBL24573265 | 0.74 | SRD5A2 (0.45) | ALDH1A1L3MBTL1TP53 | |
| SCHEMBL12514858 | 0.72 | SNCA (0.47) | TP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| CN-101103013-A | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | TDP1 4514/4885KDM4E 2653/4885PARP1 1358/4885 |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | TDP1 4269/4885KDM4E 3865/4885PARP1 4370/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TDP1 4744/4885KDM4E 2616/4885PARP1 2537/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TDP1 4744/4885KDM4E 2616/4885PARP1 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.